Lung Diseases
70 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 16-hour PP for acute lung injury | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| a wake prone positioning for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Air cleaner for pulmonary disease, chronic obstructive | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Anti Thymocyte Globulin + GM-CSF + Total Body Irradiation + ALEMTUZUMAB + RITUXIMAB + HUMAN IMMUNOGLOBULIN G + Cyclophosphamide + THIOTEPA + Mesna for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apremilast for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atibuclimab for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aviptadil for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Awake prone positioning for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Azithromycin 250 mg x3/week (3 tablets/week) + Hydroxychloroquine + Prednisone for lung diseases, interstitial | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BC006 for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Belimumab for lung diseases, interstitial | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Belumosudil 200 mg QD for pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Benralizumab for pulmonary disease, chronic obstructive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bersiporocin for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CAL101 for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Caspofungin for lung diseases, interstitial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cenicriviroc for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| clonal fetal MSCs for pulmonary disease, chronic obstructive | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CM326 dose 1 + CM326 dose 2 for pulmonary disease, chronic obstructive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Colchicine 0.5 mg for pulmonary fibrosis | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| COVID-19 CONVALESCENT PLASMA for lung diseases, interstitial | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyclosporine for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CYP Cocktail + ZIPALERTINIB for lung diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyproheptadine for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Depemokimab for pulmonary disease, chronic obstructive | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexamethasone for bronchopulmonary dysplasia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexamethasone. Dart for bronchopulmonary dysplasia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DIAG723 for pulmonary arterial hypertension | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dornase alfa for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dry Powder Inhaler + inhaled mosliciguat for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EIT-Group for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ENDS (Vaporizer/e-cig) and smoking cessation counseling for lung diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Famotidine + Celecoxib for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HB0056 for idiopathic pulmonary fibrosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HSK44459 for idiopathic pulmonary fibrosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine for respiratory distress syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine Pill + Azithromycin Pill for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine sulfate for lung diseases | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hydroxychloroquine Sulfate + Azythromycin for lung diseases | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ibuprofen for respiratory distress syndrome | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Icatibant for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Imatinib Mesylate for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LEAF-4L6715 for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Narsoplimab for respiratory distress syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pembrolizumab + lenvatinib for lung diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone decubitus for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Position for acute lung injury | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Position for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| prone positioning for respiratory distress syndrome | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prone Positioning (PP) for respiratory distress syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Quality-of-Life Assessment + Questionnaire Administration + Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine for pulmonary disease, chronic obstructive | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rentosertib for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ROC-101 for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ROC-101 for pulmonary arterial hypertension | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for pulmonary disease, chronic obstructive | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sildenafil Citrate for pulmonary disease, chronic obstructive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy + Volume Modulated Arc Therapy + NIVOLUMAB + IPILIMUMAB for lung diseases, interstitial | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solizmestrocel for bronchopulmonary dysplasia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solizmestrocel for respiratory distress syndrome | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Taladegib for idiopathic pulmonary fibrosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tozorakimab for pulmonary disease, chronic obstructive | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| TQC2731 injection for pulmonary disease, chronic obstructive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transporter Cocktail + ZIPALERTINIB for lung diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treprostinil for pulmonary arterial hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Treprostinil for pulmonary disease, chronic obstructive | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treprostinil palmitil for pulmonary arterial hypertension | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tulisokibart for lung diseases, interstitial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UC-MSC and Secretome for respiratory distress syndrome | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wharton's jelly derived Mesenchymal stem cells. for respiratory distress syndrome | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zipalertinib for lung diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |